ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AVTX vs ASMB // EV/EBITDA & P/E VALUATION

Avalo Therapeutics Inc. (NASDAQ) VS. Assembly Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: AVTX 0 — ASMB 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTX VS. ASMB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AVTX ASMB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -6.50% -28.50 ASMB /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -12.90% -9.69% -3.21 ASMB /fcf-yield <GO>
Operating Margin -60.00% -16.80% -43.20 ASMB /operating-margins <GO>
Net Profit Margin -60.00% -8.50% -51.50 ASMB /net-margins <GO>
Revenue Growth (YoY) -65.00% 153.50% -218.50 ASMB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.66 1.57 -0.91 ASMB /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 ASMB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.3 41.8 -16.50 ASMB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $399.0M $424.7M -$25.7M ASMB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AVTX REV ASMB REV AVTX GROSS % ASMB GROSS % AVTX FCF ASMB FCF
FY 2025 $59.0K $72.3M — — -$51.5M -$41.2M
FY 2024 $441.0K $28.5M — — -$49.1M -$51.1M
FY 2023 $1.9M $0 — — -$30.7M $22.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTX // BETA —
ASMB // BETA —